Who owns Silence Therapeutics plc?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of SLN from SEC Form 13F filings across 71 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 71 institutions disclosed 21.9M shares of Silence Therapeutics plc worth $235.1M — about 46.4% of shares outstanding; the largest disclosed holder is Siren, L.L.C.. Source: SEC Form 13F filings, parsed by EvidInvest.
71
13F holders
$235.1M
value, 2026 filers
46.4%
of shares outstanding (21.9M sh)
19
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of SLN's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Siren, L.L.C. | 3.3M | $36.4M | 0.7% | 7% | +13.7% |
| 2 | TCG Crossover Management, LLC | 3.0M | $33.3M | 0.8% | 6.4% | 0.0% |
| 3 | Redmile Group, LLC | 2.2M | $23.8M | 1.6% | 4.6% | 0.0% |
| 4 | Nantahala Capital Management, LLC | 1.3M | $14.8M | 0.5% | 2.9% | -37.3% |
| 5 | CITADEL ADVISORS LLC | 1.3M | $14.6M | 0.0% | 2.8% | +7.7% |
| 6 | Nextech Invest Ltd. | 952,400 | $10.5M | 0.5% | 2% | 0.0% |
| 7 | MILLENNIUM MANAGEMENT LLC | 909,279 | $10.0M | 0.0% | 1.9% | -15.4% |
| 8 | Ikarian Capital, LLC | 830,784 | $1.8M | 0.2% | 1.8% | -4.0% |
| 9 | Tetragon Partners GP Ltd | 764,256 | $8.4M | 1.3% | 1.6% | +21.3% |
| 10 | Soleus Capital Management, L.P.NEW | 630,000 | $6.9M | 0.2% | 1.3% | new |
| 11 | Balyasny Asset Management L.P.NEW | 610,980 | $6.7M | 0.0% | 1.3% | new |
| 12 | 5AM Venture Management, LLC | 476,200 | $5.2M | 1.8% | 1% | 0.0% |
| 13 | GREAT POINT PARTNERS LLC | 450,000 | $4.9M | 0.9% | 1% | -55.9% |
| 14 | MORGAN STANLEY | 403,172 | $4.4M | 0.0% | 0.9% | +515.7% |
| 15 | AMERIPRISE FINANCIAL INCNEW | 370,052 | $4.1M | 0.0% | 0.8% | new |
| 16 | JANE STREET GROUP, LLC | 369,151 | $4.1M | 0.0% | 0.8% | +265.8% |
| 17 | ADAR1 Capital Management, LLC | 338,373 | $3.7M | 0.2% | 0.7% | +96.5% |
| 18 | Schonfeld Strategic Advisors LLCNEW | 269,348 | $3.0M | 0.0% | 0.6% | new |
| 19 | UBS Group AG | 243,152 | $2.7M | 0.0% | 0.5% | -1.5% |
| 20 | BlackRock, Inc. | 219,917 | $2.4M | 0.0% | 0.5% | +7.4% |
| 21 | BANK OF MONTREAL /CAN/ | 201,734 | $2.2M | 0.0% | 0.4% | -0.6% |
| 22 | BOOTHBAY FUND MANAGEMENT, LLC | 198,347 | $2.2M | 0.0% | 0.4% | -5.1% |
| 23 | Propel Bio Management, LLCNEW | 191,733 | $2.1M | 1.1% | 0.4% | new |
| 24 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 184,519 | $2.0M | 0.0% | 0.4% | +60.1% |
| 25 | FRED ALGER MANAGEMENT, LLCNEW | 177,000 | $1.9M | 0.0% | 0.4% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.